Target intelligence / Profile preview

Cell cycle exit and neuronal differentiation protein 1 (CEND1)

Target
CEND1
Molecular classification
Other (Neuronal lineage-specific modulator), Membrane-associated protein
01

Overview

Cell cycle exit and neuronal differentiation protein 1 (CEND1), also known as BM88, is a neuronal lineage-specific transmembrane protein that plays a pivotal role in linking cell cycle exit with neuronal differentiation of neural precursor cells[1][3][5]. Expressed throughout the neuronal lineage from neural stem/progenitor cells to mature neurons, CEND1 orchestrates the timing of neuron-generating divisions, primarily promoting neuronal cell fate by downregulating proliferation-driving proteins (e.g., cyclin D1), upregulating cell cycle exit markers (e.g., p21), and suppressing Notch signaling[1][3][5]. Mechanistically, CEND1 acts through the p53-dependent Cyclin D1/pRb pathway and interacts with other regulatory proteins such as Ran-binding protein M (RanBPM) and kinase Dyrk1B to fine-tune the balance between proliferation and differentiation in developing neural tissue[2][3]. Loss-of-function models show deficits in neuronal differentiation, excess proliferation, and increased developmental apoptosis, underscoring its necessity for normal brain structure and function[3][5]. Although not a classical therapeutic target, its neurogenic and differentiation-promoting properties suggest possible utility in CNS repair or regeneration strategies[3][5].

Other names
BM88BM88 antigenFLJ90066
02

Mechanism of action

Not applicable (no direct drugging known; acts via modulation of cell cycle and neural differentiation pathways)

03

Biological functions

Cell cycle regulationPromotion of neuronal differentiationSynchronization of cell cycle exit and neuronal precursor differentiationNegative regulation of neural progenitor proliferation
04

Disease associations

Neurodevelopmental disordersNeurodegenerative disease (potential, based on neurogenic/brain repair links)Possibly implicated in response to Zika virus infection
05

Safety considerations

No therapeutic agent targeting CEND1 is in clinical use; theoretical challenges may include the potential for disturbance of neurogenesis or improper cell cycle exit leading to neurodevelopmental abnormalities if modulated in vivo
06

Biomarkers

None clearly established; CEND1 expression may act as marker for neuronal lineage/differentiation states in research contexts

Beyond the preview

Go deeper on Cell cycle exit and neuronal differentiation protein 1 (CEND1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cell cycle exit and neuronal differentiation protein 1 (CEND1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call